The name sounds like a result from a doctor's appointment. That is the joke and the strategy. 120/80 GROUP did not need a paragraph of positioning to announce its territory. The slash did the work. When Rob Cronin and Jen Long launched 120/80 MKTG in November 2018, they chose a corner of healthcare that still felt like a category within a category: digital health. Large agencies could point to drug, device, hospital and insurance practices. The new firm pointed at the software, data and service models beginning to rearrange all four.
That choice was more consequential than the list of services that followed. The firm offered strategy, messaging, media relations, content, social, analyst relations, events and measurement. Plenty of agencies could produce that menu. Fewer had built their identity around understanding why a virtual-care company speaks differently to a patient, a clinician, a health plan, an employer and an investor - often in the same week.
120/80's product, in other words, was context. The company says its communications work is meant to affect sales, investment, partnerships and hiring, not merely fill a clipping report. That ambition explains the firm's fondness for words like outcomes, share of voice and category leadership. It also explains why data analytics sits beside creative talent in its own description of the work.
The founding wagerA small door into a very large room
Cronin and Long had made a bet about where healthcare's center of gravity was moving. Remote monitoring, predictive algorithms, data aggregation and virtual care were not accessories to the system. They were becoming part of the system's plumbing. Then COVID-19 arrived. Clinicians went online, employers added digital benefits and patients learned that an appointment could begin on a screen.
The pandemic did not validate every digital-health company. It did something more useful for an agency: it erased the old boundary around the category. Cronin later wrote that even an evangelist like him was stunned by the pace of integration. What failed first was the framing. Digital health could no longer be treated as a neat side market.
That observation changed the architecture of the business. In April 2024, the company announced 120/80 GROUP as a holding company above two consultancies. The original 120/80 MKTG remained focused on digital health. AOx3, based in Silicon Valley and New York, was created for organizations trying to prove that technology and artificial intelligence can improve human health. Gary Grates became group president; Long became managing partner and chief client officer of 120/80 MKTG; veteran technology communicator Mike Fay took the corresponding role at AOx3.
“Digital health is no longer a discrete market within healthcare.”Rob Cronin, announcing the group structure
How the machine worksTwo front doors, four rooms behind them
The structure is the clearest description of what the company actually sells. Clients enter through 120/80 MKTG or AOx3. Behind those brands sit four shared specialist units. STUDIOS makes editorial, video, podcasts, webinars and executive content. CORPORATE handles crises, change, public affairs, internal communications, IPOs and M&A. INSIGHTS maps influencers, ranks media and conferences, benchmarks competitors and produces research. GROWTH works on demand generation, sales enablement, acquisition and product adoption.
This is a fee-based consulting business, not a subscription product. Engagements combine counsel, research and execution in custom scopes. Buyers are founders, CEOs, communications and marketing leaders, investors and advisors. Its public client roster has included the American Cancer Society, Coalition for Health AI, Walmart, Twin Health, Vim and a long list of digital-health companies. Recent company posts have also discussed work involving Withings, Color, athenahealth, Rad AI, Abridge and Aidoc.
The useful differenceAttention is plotted against evidence
The most distinctive part of the offer may be INSIGHTS. In 2025, 120/80 introduced a Life Sciences Innovation Index covering more than 20 Fortune 500 pharmaceutical and medical-device organizations. The study separates substance - patents, published research, investment and AI talent - from prominence, including media visibility and brand awareness. A company can be loud but thin, or consequential but overlooked. The interesting clients sit in the mismatch.
High substance, low prominence
High substance, high prominence
Low substance, low prominence
Low substance, high prominence
This turns research into more than decoration for a press release. It gives an executive team four sharper questions: What counts as innovation in our market? Are we attracting the talent to support that claim? Does our investment match the story? Is the market giving us credit? The index also becomes an entry point for briefings and advisory work. Research creates a conversation; the agency sells help acting on the answer.
The same idea appears in the firm's emphasis on conference and media rankings. Healthcare has a peculiar calendar of crowded stages - J.P. Morgan, HLTH, ViVE, HIMSS, ASCO and others. Winning attention for a day is easy to confuse with owning a category. 120/80's method is to decide which audiences and moments matter, build an evidence-bearing point of view, and measure whether the client moved relative to its competitors.
The part worth borrowingSpecialize in the problem, then expand with it
The portable lesson is not to put a medical reading in your company name. It is to pick a market where knowledge compounds. Every healthcare launch, transaction and policy argument adds relationships and judgment that can make the next assignment better. Then turn some of that accumulated knowledge into repeatable tools: a benchmark, an index, a conference ranking, an influencer map. Services create revenue; intellectual property creates a reason to call this firm rather than another one.
The second lesson is organizational. 120/80 did not discard its original brand when AI became the loudest new theme. It kept the digital-health agency, opened a second front door for AI and life sciences, and shared expensive capabilities behind both. That lets a client see a specialist while the business reuses research, production and senior counsel.
Where the model earns its keep
High-stakes, regulated markets with technical products, many audiences and a premium on senior judgment. The client must value category fluency and measurable outcomes.
Where it loses leverage
Commodity execution, small one-off projects or broad consumer work where deep healthcare context adds little. A specialist model also weakens if expertise becomes a slogan rather than a staffed capability.
There is a constraint hidden inside the strategy. A consultancy that promises to understand clinicians, investors, policymakers, payers and patients must keep hiring people who have actually worked across those worlds. Its 2024 and 2025 leadership additions read like maintenance on that promise: corporate and change counsel, technology communications, life-sciences experience and national healthcare media relationships. Expertise is not a positioning line here. It is the cost of goods.
By 2025, the company was also trying to own the room itself. It announced AGENTIC, a conference concept for AI and life sciences, and later expanded an interview series called Incumbents & Insurgents. This is a familiar agency move with a sharper strategic purpose. The firm is no longer only helping clients enter other people's conversations. It is building the research, editorial formats and gatherings where those conversations happen.
The slash in 120/80 still points to healthcare. But the story of the company is about another dividing line, the one between a sector and the technology remaking it. Cronin and Long started on one side. The market erased the boundary. Their response was to build a larger house exactly where the line used to be.